Te­va spin­out de­lays NASH IPO while Galera prices be­low range

A NASH-fo­cused spin­off of Te­va Phar­ma­ceu­ti­cals de­layed its IPO and Galera priced be­low its $14-$16 range as the pub­lic wa­ters grow murki­er.

Tout­ing an FGF21 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER